Treatment with RMC-4998 and RMC-4550 did not provide added benefit, whereas addition of anti-PD-1 to the RMC-4998 and RMC-4550 combination suppressed tumour growth further (Fig. 4f), indicating that this combination partially sensitises this immune cold model to anti-PD-1. Here, PDCD1 is linked to neoplasm.